This week, what is probably probably the most consequential listening to within the historical past of the US, and certainly the worldwide hashish trade, is happening in Arlington, Virginia.
The Administrative Legislation Choose (ALJ) listening to, anticipated to decide whether or not adult-use hashish follows medical hashish into Schedule III, is now in its second week of three.
Within the 10 or so weeks since performing Lawyer Normal Todd Blanche issued a last order transferring two classes of hashish from Schedule I to Schedule III, specifically hashish contained in an FDA-approved drug product (overlaying solely Epidyolex), and hashish topic to a state medical hashish licence, the rationale for investing within the sector has already shifted meaningfully.
As Enterprise of Hashish reported final month, a few of the US’ largest MSOs are awaiting the result of the ALJ listening to earlier than providing their inventory to traders on the nation’s premier inventory exchanges. Though the recategorisation of adult-use hashish would save these corporations a serious headache, the sensible funding technique might already be to give attention to the medical hashish vertical.
The pathway, not the plant
In the course of the first ‘inexperienced wave’ of the late 2010s and early 2020s, the businesses that commanded probably the most consideration had been those in a position to increase probably the most cash and broaden the quickest.
Having realized the laborious manner that this mannequin was inherently flawed for each for the businesses and their traders, the eye has shifted to corporations in a position to formulate, standardise and clinically validate a product, with the provision chain in place to dispense it extensively.
The brand new holy grail for hashish operators is now not sheer monetary heft, however specialists with properly educated drug growth methods and watertight IP.
A Schedule III substance may be manufactured, distributed and disbursed by an entity holding a sound DEA registration, researched with out the constraints that made Schedule I research so troublesome, and brought by the FDA approval course of as a prescription drugs.
With that in thoughts, will the approval of adult-use hashish for rescheduling render this level completely redundant?
Mark E. Merritt, a former fairness analysis analyst who now writes on the worldwide hashish trade, argues that wider rescheduling commoditises hashish. In markets like Canada and even Germany’s extra restricted medical market, the inflow of hashish has pushed a race in direction of low-price, high-THC hashish.
What’s tougher to commoditise are the proprietary formulations, supply mechanisms, medical information and a longtime model. A extra liberal market, on this studying, hollows out the cultivators and pushes worth in direction of the businesses that personal that layer.
Rescheduling additionally leaves the pharmaceutical route untouched. It doesn’t allow hashish to be offered as an peculiar product throughout state strains, a cannabinoid drugs nonetheless has to finish the complete New Drug Utility course of to be prescribed nationally. That route is open solely to corporations already doing the formulation and medical work, no matter what occurs to adult-use.
Most traders, Merritt argues, learn hashish corporations off their share charts and have missed the companies being constructed from the bottom as much as develop pharmaceutical medicines. He provides that the variety of companies combining low-cost provide, a proprietary formulation platform, an actual income base and a medical pipeline is near none.
READ MORE…
Avicanna, a case examine
Avicanna, listed on the Toronto Inventory Alternate as AVCN, is a commercial-stage biopharmaceutical firm that has spent a decade constructing round cannabinoid drugs somewhat than leisure provide.
It runs 4 related enterprise models. Rho Phyto is its portfolio of proprietary, standardised non-inhaled medical merchandise throughout oral, sublingual, topical and transdermal codecs. MyMedi.ca, the previous Customers Drug Mart medical hashish platform it took over in 2023, hyperlinks sufferers with physicians and pharmacists and generates the majority of present income.
A pharmaceutical pipeline develops indication-specific candidates in areas together with power ache, dermatology and neurological issues. Underpinning all of it’s Santa Marta Golden Hemp (SMGH), the 60%-owned Colombian subsidiary that provides energetic pharmaceutical elements and cultivates natural, GACP-certified flower in partnership with Grupo Daabon, one of many largest natural agriculture teams in South America.
The business argument is that these models reinforce each other. Colombian provide feeds low-cost, high-quality enter right into a formulation enterprise, which is commercialised by a medical platform that generates real-world affected person information, which in flip seeds the medical pipeline.
Merritt describes the end result as a self-reinforcing intellectual-property system somewhat than a group of property, and argues it’s transferable to new markets exactly as a result of Avicanna shouldn’t be the finished-product producer however the holder of the formulations and supply know-how, together with a fast-emulsion platform related to the edibles and beverage classes.
The corporate had its strongest 12 months to this point. It reported income of C$25.5m for the 12 months to December 31, 2025, which was broadly flat on 2024 revenues.
Though its income did not develop, its gross margin rose to 53% and it reported constructive adjusted EBITDA of C$0.31m within the fourth quarter, seeing it close to break-even for the 12 months as a complete. It carries no debt.
All of that sits in opposition to a market capitalisation of round C$15 million, with the shares buying and selling close to C$0.13. Merritt believes the corporate is considerably undervalued.
The market’s scepticism, nevertheless, shouldn’t be irrational. Income has been flat for a number of quarters, and the medical-affairs funding wanted to reignite top-line development is strictly what a capital-starved firm struggles to fund. The inventory has fallen from a peak above C$7 to pennies. Its largest shareholder has been promoting steadily for greater than a 12 months, an overhang that caps the value no matter what the underlying enterprise does, and the corporate has repeatedly raised small quantities of fairness to remain funded, most lately by non-public placements in February and June.
Merritt reads the falling share value because the product of a promoting shareholder and unfavorable sentiment somewhat than a deteriorating enterprise, and due to this fact as the chance itself. He believes a extra medical, rescheduled world market will ultimately power a re-rating.
That could be a thesis, not a truth, and his personal disclosure that he holds the inventory ought to be learn alongside it. He goes on to take a position that cultivation prices may fall to US$0.10 to US$0.25 per gram, based mostly on interviews with chief government Aras Azadian, alongside a long-run valuation working into the billions.
Proceedings in Arlington are as a consequence of conclude no later than 15 July, although the ALJ’s advice is non-binding and the DEA administrator faces no deadline to behave on it.
Regardless of the consequence, the route the April order appears unlikely to reverse. worth in a extra medical, extra regulated market retains migrating in direction of corporations that may formulate, standardise, dispense by regulated channels and generate medical proof.
